Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
Protocol ID
Firefly-2
Disease (Sub Disease)
Low-Grade Glioma
Diagnosis Stage
Newly diagnosed
Sponsor
Day One Biopharmaceuticals, Inc.
Collaborators
SIOPe Brain Tumor Group LOGGIC Consortium
Links
Trial Status
Preparing to Open
Study Type
Treatment
Phase
Phase 3
Age Eligibility
up to 25 Years
International registry ID's
NCT05566795
| Study Title | A Phase 3 Randomized International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy |
|---|---|
| Protocol ID | Firefly-2 |
| Disease (Sub Disease) | Low-Grade Glioma |
| Diagnosis Stage | Newly diagnosed |
| Sponsor | Day One Biopharmaceuticals, Inc. |
| Collaborators | SIOPe Brain Tumor Group LOGGIC Consortium |
| Links | https://clinicaltrials.gov/ct2/show/NCT05566795 |
| Trial Status | Preparing to Open |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | up to 25 Years |
| International registry ID's | NCT05566795 |